Healthcare Industry News:  GSK 

Biopharmaceuticals Personnel

 News Release - February 14, 2007

TaiGen Appoints Dr. Luke Lin VP of Clinical Research & Development

TAIPEI, Taiwan, Feb. 14 (Healthcare Sales & Marketing Network) -- TaiGen Biotechnology Inc., a private Taiwan based biopharmaceutical company developing novel therapeutics to treat infectious diseases, cancer and diabetic complications, today announced the appointment of Dr. Luke Lin as Vice President of Clinical Research & Development. Reporting to Ming-Chu Hsu, Ph.D., President and Chief Executive Officer. Dr. Lin will be responsible for managing the company's global clinical and regulatory activities.

''We are excited to have Luke on our team, as he brings to the company a broad expertise and strong track record in advancing drug discovery programs into clinical development.'' said Dr. Hsu. '' His extensive experience in drug development and, in particular, his strength in leading clinical development programs in Asia Pacific as well as Indo-China will prove to be major assets as we progress our novel therapeutic programs into further clinical development and the market.''

Dr. Lin was the Medical Director at GlaxoSmithKline (GSK) Singapore/Malaysia and GSK Taiwan. Prior to this, Dr. Lin had been with Merck (Singapore) Pte Ltd. and SciGen Pte Ltd. Dr. Lin also spent 3 years as a Research Scientist and Principal Investigator with National University of Singapore. He earned his M.D. from Shanghai 1st Medical University in China and D. Phil. (Ph.D.) degree in Virology from the Royal Free Hospital School of Medicine of the University of London.

About TaiGen Biotechnology

TaiGen Biotechnology ( ) is a leading pharmaceutical company based in Taiwan and has a wholly-owned subsidiary in Beijing, China. The company is developing novel therapeutics to treat infectious diseases, cancer and diabetic complications. TaiGen has established a full capacity to conduct new drug research and clinical development in China, US and other countries. The company is building its product pipeline through internal research and in-licensing of late clinical stage products. In addition to the clinical development of Nemonoxacin, the company has pre-clinical drug candidates for treating hepatitis C virus infection, cancer and diabetic related complications including diabetic critical limb ischemia and retinopathy.

Source: TaiGen Biotechnology

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.

FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.